Referencia número: HY-N0911

Rehmannioside A

1 Cited Publications

Revisión del cliente

Based on 1 publication(s) in Google Scholar

Rehmannioside A is a compound that can be isolated from Rehmanniae radix. Rehmannioside A is an inhibitor of CYP3A4, 2C9 and 2D6, with IC₅₀ values of 10.08, 12.62 and 16.43 μM, respectively. Rehmannioside A has anti-inflammatory, antioxidant, anti-apoptosis, anti-ferroptosis, cognitive improvement and neuroprotective activities. Rehmannioside A can be used for the research of nervous system and inflammation-related diseases.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.95%
No. CAS: 81720-05-0
Fòrmula: C₂₁H₃₂O₁₅
Peso molecular:524.47

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Rehmannioside A Chemical Structure

No. CAS: 81720-05-0

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

IC₅₀ & Target^[1]^[2]^[3]

CYP2C9

12.62 μM (IC₅₀)

CYP3A4

10.08 μM (IC₅₀)

CYP2D6

16.43 μM (IC₅₀)

iNOS

Bcl-2

COX-2

Ver todos los productos específicos de isoformas NF-κB :

Ver todos los productos específicos de isoformas p38 MAPK :

Ver todos los productos específicos de isoformas Cytochrome P450 :

Ver todos los productos específicos de isoformas MEK :

Ver todos los productos específicos de isoformas Bcl-2 Family :

Ver todos los productos específicos de isoformas NO Synthase :

Ver todos los productos específicos de isoformas COX :

Ver todos los productos específicos de isoformas PARP :

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	>10 μM Compound: 16	Cytotoxicity against human A2780 cells by MTT assay Cytotoxicity against human A2780 cells by MTT assay	[PMID: 26859776]
A549	IC₅₀	>10 μM Compound: 16	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 26859776]
Bel-7402	IC₅₀	>10 μM Compound: 16	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 26859776]
BGC-823	IC₅₀	>10 μM Compound: 16	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 26859776]
HT-29	IC₅₀	>10 μM Compound: 16	Cytotoxicity against human HT-29 cells by MTT assay Cytotoxicity against human HT-29 cells by MTT assay	[PMID: 26859776]

In Vitro

Rehmannioside A (0-100 μM; 24 h) can improve high-glucose-induced decrease in cell viability and inhibit apoptosis and oxidative stress in HK2 cells (increasing the activities of SOD and CAT, reducing the levels of MDA, and decreasing LDH release and ROS production). The mechanism is involved in the inhibition of p38 MAPK and ERK1/2 phosphorylation^[1].
Rehmannioside A (0-80 μM; 48 h) inhibits the release of pro-inflammatory mediators and promotes M2 polarization in LPS (HY-D1056)-treated BV2 cells. The mechanism is related to the inhibition of NF-κB and MEK signaling pathways^[2].
Rehmannioside A (80 μM; 48 h) reduces neuronal apoptosis and restores the expression of anti-apoptotic protein Bcl-2 in the co-culture system of PC12 and BV2 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

HK2 cells treated high-glucose
Concentration:

20, 40 and 80 μM
Incubation Time:

24 h
Result:

Significantly inhibited the levels of BAX and cleaved PARP proteins and increased Bcl-2 levels.

Western Blot Analysis^[2]

Cell Line:

BV2 cells treated LPS (HY-D1056)
Concentration:

0, 20, 40 and 80 μM
Incubation Time:

Pretreated with 24 h, then co-incubation for 24 h
Result:

Inhibited the levels of iNOS and COX-2.

In Vivo

Rehmannioside A (80 mg/kg; intraperitoneal injection; 28 days) exerts a beneficial effect in a rat model of spinal cord injury^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female SD rats (200-250 g) with spinal cord injury^[2]
Dosage:

80 mg/kg
Administration:

Intraperitoneal injection; 28 days
Result:

Significantly improved the behavioural and histological indices.
Promoted M2 microglial polarization.
Alleviated neuronal apoptosis.
Increased motor function recovery.

Chemical Information

No. CAS 81720-05-0
Appearance Solid
Peso molecular 524.47
Fòrmula C₂₁H₃₂O₁₅
Color White to off-white
SMILES

OC[C@@]1([C@]([C@@H]2O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]([C@H]3O)CO[C@H]([C@@H]([C@H]4O)O)O[C@@H]([C@@H]4O)CO)([H])[C@](C=CO2)([H])[C@@H]5O)[C@@]5([H])O1
Structure Classification
- Terpenoids
- Iridoids
Initial Source
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

J Ethnopharmacol

Radix Rehmanniae Praeparata promoted zebrafish fin regeneration through aryl hydrocarbon receptor-dependent autophagy. [Abstract]

2024 Sep 15:331:118272. PMID: 38710459

Solvente y solubilidad

In Vitro:

H₂O : ≥ 100 mg/mL (190.67 mM)

DMSO : 50 mg/mL (95.33 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9067 mL

9.5334 mL

19.0669 mL

5 mM

0.3813 mL

1.9067 mL

3.8134 mL

10 mM

0.1907 mL

0.9533 mL

1.9067 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.25 mg/mL (2.38 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1.25 mg/mL (2.38 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (285 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Huai L, et al. Rehmannioside A protects against high glucose-induced apoptosis and oxidative stress of renal tubular epithelial cells by inhibiting the MAPK pathway. Tropical Journal of Pharmaceutical Research, 2021, 20(8): 1553-1558.

[2]. Xiao S, et al. Rea regulates microglial polarization and attenuates neuronal apoptosis via inhibition of the NF-κB and MAPK signalings for spinal cord injury repair. J Cell Mol Med. 2021 Feb;25(3):1371-1382. [Content Brief]

[3]. Wang C,et al. Rehmannioside A inhibits the activity of CYP3A4, 2C9 and 2D6 in vitro. Xenobiotica. 2024 Apr;54(4):195-200. [Content Brief]

[4]. Fu C, et al. Rehmannioside A improves cognitive impairment and alleviates ferroptosis via activating PI3K/AKT/Nrf2 and SLC7A11/GPX4 signaling pathway after ischemia. J Ethnopharmacol. 2022 May 10;289:115021. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	1.9067 mL	9.5334 mL	19.0669 mL	47.6672 mL
	5 mM	0.3813 mL	1.9067 mL	3.8134 mL	9.5334 mL
	10 mM	0.1907 mL	0.9533 mL	1.9067 mL	4.7667 mL
	15 mM	0.1271 mL	0.6356 mL	1.2711 mL	3.1778 mL
	20 mM	0.0953 mL	0.4767 mL	0.9533 mL	2.3834 mL
	25 mM	0.0763 mL	0.3813 mL	0.7627 mL	1.9067 mL
	30 mM	0.0636 mL	0.3178 mL	0.6356 mL	1.5889 mL
	40 mM	0.0477 mL	0.2383 mL	0.4767 mL	1.1917 mL
	50 mM	0.0381 mL	0.1907 mL	0.3813 mL	0.9533 mL
	60 mM	0.0318 mL	0.1589 mL	0.3178 mL	0.7945 mL
	80 mM	0.0238 mL	0.1192 mL	0.2383 mL	0.5958 mL
H₂O	100 mM	0.0191 mL	0.0953 mL	0.1907 mL	0.4767 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Rehmannioside A

1 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Rehmannioside A

Covalent Screening Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Endoplasmic Reticulum Stress Compound Library

Terpenoids Library

Glycolysis Compound Library

Pyroptosis Compound Library

Traditional Chinese Medicine Active Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Mitochondria-Targeted Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Natural Product Library Plus

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Polysaccharides Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library